Dai Doctor Chief Physician

The First Affiliated Hospital, Sun Yat-sen University · Oncology Department · Chief Physician

Associate Chief Physician at Sun Yat-sen University’s First Affiliated Hospital, with a Master’s in Oncology. Holds committee roles in Guangdong and Guangzhou anti-cancer associations. Published 12 papers as first/corresponding author in journals like Gene and Oncotarget, focusing on cancer susceptibility polymorphisms, microRNA roles, and treatment biomarkers.

**Medical Expertise:** Proficient in the diagnosis of common tumors and medical oncology treatments including chemotherapy, targeted therapy, and biological immunotherapy. Experienced in comprehensive disease assessment, the latest advances, and integrated treatment for malignant tumors across various body sites, such as lung cancer, breast cancer, gastric cancer, colorectal cancer, cholangiocarcinoma, pancreatic cancer, prostate cancer, esophageal cancer, liver cancer, melanoma, soft tissue sa

Dai Doctor
Doctor Photo
Basic Information

About Dr. Dai Doctor

Hospital
The First Affiliated Hospital, Sun Yat-sen University
Title
Chief Physician
Department
Oncology Department
Years of Practice
28 years (1998 — present)
**Education and Professional Experience:** 1992.9 – 1997.6: Bachelor's Degree in Clinical Medicine, Zhongshan Medical University 2009.9 – 2012.6: Master's Degree in Oncology, Sun Yat-sen University 1997.7 – 2002.6: Resident Physician, The First Affiliated Hospital, Sun Yat-sen University 2002.6 – 2015.12: Attending Physician, The First Affiliated Hospital, Sun Yat-sen University 2016.1 – Present: Associate Chief Physician, The First Affiliated Hospital, Sun Yat-sen University **Professional Affiliations:** Youth Committee Member, Cancer Rehabilitation and Palliative Care Committee, Guangdong Anti-Cancer Association Committee Member, Tumor Prevention and Treatment Committee, Guangdong Health Management Association Committee Member, Gastric Cancer Committee, Guangzhou Anti-Cancer Association **Publications:** **A: First Author/Co-first Author/Corresponding Author** 1) Poly (AT) deletion/insertion polymorphism of the XPC gene contributes to urinary system cancer susceptibility: A meta-analysis. Gene, 2013, Oct 10;528(2):335-42. (IF= 2.138) First Author/Corresponding Author 2) XPC gene polymorphisms contribute to bladder cancer susceptibility: a meta-analysis. Tumour Biol, 2014 Jan;35(1):447-53. (IF= 3.611) First Author/Corresponding Author 3) Xeroderma pigmentosum complementation group D (XPD) gene polymorphisms contribute to bladder cancer risk: a meta-analysis. Tumour Biol, 2014 Apr;35(4):3905-15. (IF= 3.611) 4) A novel role for microRNA-129-5p in inhibiting ovarian cancer cell proliferation and survival via direct suppression of transcriptional co-activators YAP and TAZ. Oncotarget, 2015 Apr 20;6(11):8676-86. (IF= 6.359) 5) Osterix transcriptional factor is involved in the metastasis of human breast cancers. Oncol Lett, 2015 Sep;10(3): 1870-1874. (IF= 1.554) 6) Hypertension as a predictive biomarker for efficacy of bevacizumab treatment in metastatic colorectal cancer: A meta-analysis. J BUON, 2014 Dec;19(4): 917-24. (IF= 0.741) Corresponding Author 7) Transarterial chemoembolization vs. conservative treatment for unresectable infiltrating hepatocellular carcinoma: A retrospective comparative study. Mol Clin Oncol, 2014 Nov;2(6):1047-1054. 8) The Glasgow Prognostic Score predicts poor survival in cisplatin-based treated patients with metastatic Nasopharyngeal Carcinoma. PLoS One, 2014 Nov 13;9(11):e112581. (IF= 3.234) 9) Prediction of occult cervical lymph node metastasis in clinically negative supraglottic squamous cell carcinoma. Head Neck Oncol, 2012, Oct 27;4(3):69. 10) PSCA s2294008 C>T and rs2976392 G>A polymorphisms contribute to cancer susceptibility: evidence from published studies. Genes Cancer, 2015 May;6(5-6):254-64. 11) Experimental study on synergistic treatment of hepatocellular carcinoma with β-glucosylceramide and HBsAg-DC vaccine [J/CD]. Chinese Archives of General Surgery (Electronic Edition), 2013, 7(4):298-302. 12) Clinical study of octreotide in preventing irinotecan-induced delayed diarrhea. New Medicine, 2012, 43(3):155-158. **B: Other Ranked Publications** 13) Zhou H, Wei J, Dai Q, Wang L, Luo J, Cheang T, Wang S. CaCO3/CaIP6 composite nanoparticles effectively deliver AKT1 small interfering RNA to inhibit human breast cancer growth. Int J Nanomedicine, 2015 Jul 1;10:4255-66. (IF= 4.383) 14) Qu MH, Zeng RF, Fang S, Dai QS, Li HP, Long JT. Liposome-based co-delivery of siRNA and docetaxel for the synergistic treatment of lung cancer. Int J Pharm, 2014 Oct 20;474(1-2):112-22. (IF= 3.65) 15) Chen C, Sun P, Rong J, Weng HW, Dai QS, Ye S. Short Course Radiation in the Treatment of Localized Rectal Cancer: A Systematic Review and Meta-Analysis. Sci Rep. 2015 Jun 9;5:10953. (IF= 5.578) 16) Long J, Zhou B, Li H, Dai Q, Zhang B, Xing S, Zeng Z, Chen W, Yang J. Improvement of HbsAg Gene-Modified Dendritic Cell-Based Vaccine Efficacy by Optimizing Immunization Method or the Application of β-glucosylceramide. Immunol Invest. 2013 Jan 16;42(2):137-55. (IF= 1.991) 17) Long JT, Cheang TY, Zhuo SY, Zeng RF, Dai QS, Li HP, Fang S. Anticancer drug-loaded multifunctional nanoparticles to enhance the chemotherapeutic efficacy in lung cancer metastasis. J Nanobiotechnology. 2014 Sep 30;12(1):37. (IF= 4.115) 18) Wang TB, Dai QS, Wei XQ, Lin WH, Shi HP, Dong WG. CXCR4 RNA interference sequence screening and its effect on the growth of colon cancer SW480 cells [J/CD]. Chinese Archives of General Surgery (Electronic Edition), 2012, 6(5):394-399. **Monograph:** Associate Editor-in-Chief, *Practical Diagnosis and Treatment of Gastrointestinal Malignancies*, Guangdong Science and Technology Press.
Schedule

Dr. Dai Doctor — Outpatient Schedule

Weekly clinic, including specialist and surgery days. Book 3-7 days in advance.

Clinic: The First Affiliated Hospital, Sun Yat-sen University · Oncology Department
On Duty
Off Duty
Period Morning
08:00-12:00
Afternoon
14:00-17:30
Evening
18:30-20:30
Mon On Duty
09:00 - 12:00
Off Duty Off Duty
Tue Off Duty Off Duty Off Duty
Wed Off Duty On Duty
14:00 - 17:00
Off Duty
Thu Off Duty Off Duty Off Duty
Fri Off Duty Off Duty Off Duty
Sat Off Duty Off Duty Off Duty
Sun Off Duty Off Duty Off Duty
Note: Actual clinic hours are subject to the hospital's daily notice. Please call the Dovecure 24h hotline 400-888-0000 to confirm before booking.

Rationale for Precision

Senior Medical Advisory Team — With an average of over five years of clinical experience, the team has supported over 1,000 families in accessing coordinated, high-quality medical care in China.

Book your dedicated advisor now

Senior Medical Advisory Team — With an average of over five years of clinical experience, the team has supported over 1,000 families in accessing coordinated, high-quality medical care in China.

24/7 medical consultation +86 18126771334 (iMessage)
Email Consultation cure@dovecure.com
WeChat dovecure_care
Cart
Your cart is empty
Continue shopping
{{ item.sku_code }} - {{ item.variant_label }} {{ item.item_type_label }}
{{ item.price_format }}
{{ item.subtotal_format }}
Total {{ totalAmount }}
Checkout View Cart
Consult